Maravai Lifesciences Holdings Inc (MRVI) Q1 2025 earnings call Highlights: navigate growth …

• Revenue: 47 million US dollars for the first quarter of 2025.

• Nucleic acid production (NAP) income: 29 million US dollars in the first quarter of 2025.

• Biological security tests (BST) income: 18 million US dollars in the first quarter of 2025.

• Gaap -Netto -Trocht: 53 million US dollars for the first quarter of 2025.

• Adapted EBITDA: Negative 11 million US dollars for the first quarter of 2025.

• Basic and diluted EPS: Loss of $ 0.21 per share for Q1 2025.

• Intended EPS: Loss of $ 0.08 per share for Q1 2025.

• Cash and cash equivalent: 285 million US dollars at the end of the first quarter of 2025.

• Long -term debt: 298 million US dollars at the end of the first quarter of 2025.

• Cash used for the company: 9 million US dollars for quarter 2025.

• Investment expenses: 4 million US dollars for the first quarter of 2025.

• Depreciation and amortization: 13 million US dollars for the first quarter of 2025.

• Interest effort: 4 million US dollars for the first quarter of 2025.

• Stock -based remuneration: 10 million US dollars for the first quarter of 2025.

• Total tactics: 255 million stocks at the end of March 2025.

Appearance date: May 12, 2025

You can find the complete copy of the earnings call in the complete earnings call.

• Maravai Lifesciences Holdings Inc (Nasdaq: MRVI) recorded sales of $ 47 million for the first quarter of 2025, with expectations exceeded and growth occurred compared to the previous quarter.

• The NAP segment (NAP) of the nucleic acid (NAP) recorded a sales climb to 29 million US dollars, which indicates the growth of its core business.

• The company started new innovative technologies such as the Poly (A+) line to improve the MRNA performance, which could expand mRNA clinical applications.

• Maravai Lifesciences Holdings Inc (Nasdaq: MRVI) has successfully integrated the recent acquisitions and improved its oligo product portfolio and enzyme functions.

• The company signed five additional CLEANCAP license and supply agreements and expanded its customer base and the market range.

• Maravai Lifesciences Holdings Inc (Nasdaq: MRVI) recorded a GAAP -Nettoverlust of $ 53 million for the first quarter of 2025 compared to a loss of USD 23 million in the previous year.

• The adapted EBITDA was negative 11 million US dollars, which reflected the challenges when achieving profitability.

• The company has not yet received any guaranteed orders for Cleancap of top customers with commercially approved vaccines.

• There are continuing uncertainties in relation to tariffs and trade dynamics that could affect future operations and costs.

• The segment of the biological security test (BST) from China is strong in the first quarter, but consists of potential risks of geopolitical tensions and tariffs.

Q: Trey, in their prepared remarks, they spoke to a mixture of new attempts and some who were mixed, which in my opinion was basically a laundry for the neighborhood. What do you tell you about the focus areas for the new attempts and vice versa those who are set? Why are they going away? A: William Martin, CEO: The preclinical was relatively flat, but the clinic actually had additions. This can point to projects in the later stage, since conservatism is financed. We see a shift in covid and infectious diseases to a wider area of ​​mRNA-supported modalities. The clinical expansion is obvious while preclinical flat remains.